Apotex Manufacturing Violations Could Delay Launch Of Taxotere Generic
Executive Summary
FDA's warning letter to Apotex for continued manufacturing violations could delay the launch of the company's generic version of the cancer drug Taxotere (docetaxel)
You may also be interested in...
Apotex’s Generic Approvals Delayed By FDA Paperwork Snafu, Lawsuit Says
The agency’s “inexcusable delay” in granting final approval of Apotex’s ANDAs for Avapro and Avalide has caused the company to “fall fatally behind” in the marketplace now that 180-day exclusivity for the antihypertensive agents has expired, the manufacturer alleges.
FDA Import Alert Lifted, Apotex Says; Will Lipitor ANDA Approvals Be Far Behind?
Apotex’s announcement that FDA is lifting an import alert on products manufactured at two Canadian facilities could be interpreted as a good sign for the near-term availability of Lipitor generics, either from first-filer Ranbaxy Laboratories Ltd. or subsequent ANDA filers.
FDA Import Alert Lifted, Apotex Says; Will Lipitor ANDA Approvals Be Far Behind?
Apotex’s announcement that FDA is lifting an import alert on products manufactured at two Canadian facilities could be interpreted as a good sign for the near-term availability of Lipitor generics, either from first-filer Ranbaxy Laboratories Ltd. or subsequent ANDA filers.